Goals & Strategy

#CommittedToLife: the health and well-being of patients is Fresenius’ top priority. For more than 100 years, we have been combining cutting-edge technology with a focus on patients, paving the way for the therapies of the future. We save and improve lives and health. We provide access to affordable and innovative medical products and clinical care of the highest quality.

Fresenius businesses geared towards driving forces in healthcare

The global healthcare sector is growing and changing rapidly – driven by demographic shifts, technological advancements, and evolving patient needs. It is one of the world’s largest industries, offering exceptional growth opportunities. These secular growth drivers are here to stay:

• Ageing global population: The world’s population is aging significantly, increasing demand for healthcare services.
• Higher prevalence of chronic diseases: Chronic conditions are driving higher healthcare spending worldwide.
• Growing healthcare spending: Across geographies, healthcare spending as a share of GDP continues to rise. In the U.S., for example, spending approached nearing $5 trillion in 2023 based on CMS data. At +7.5%, this is the biggest increase in decades!
• Technological advancements: Digital solutions and AI will play an increasingly role in quality and productivity 
• Demand for highly-skilled workforce: Attracting top talent is essential to stay at the forefront of innovative healthcare 

Fresenius is positioned to benefit from these trends as a provider of system-critical products, medicines, services, and care. We geared our businesses towards these driving forces and are committed to staying at the forefront, ensuring our businesses remain system-relevant and future-ready.
 

Covering the entire patient journey

With +100 years of experience, we are saving and improving human lives with affordable, accessible, and innovative healthcare products and the highest quality in clinical care. Our USP is our unique positioning: we cover the entire patient journey with a broad portfolio range – right at the critical spots in care – capable of advancing therapies on many levels. With Fresenius Kabi and Fresenius Helios, we address, lead and meet evolving patient needs across three therapy platforms: 

• (Bio)Pharma including clinical nutrition: This includes our broad range of essential IV Generics and IV Fluids, Enteral and Parenteral Clinical Nutrition, and our fast-growing Biosimilars business.
• MedTech: We are addressing cutting-edge technology in Transfusion & Cell Therapies and the Infusion & Nutrition Systems space.
• Care Provision: This is where we provide high-quality and innovative treatments through our market-leading networks of hospitals and outpatient facilities in Germany and Spain – treating 26 million patients every year!

With this strategy, we address the driving forces in healthcare that will change the pattern of growth. All business at Fresenius Kabi and Fresenius Helios have leading market positions in attractive markets and grow meaningfully organically. We are part of the solution of innovative healthcare and future therapies: 

• Health Equity: Providing affordable and accessible products and services
• Integrated therapies: Driving multimodal therapies across three platforms 
• Digital solutions and AI: Enhancing clinical outcomes, quality and productivity 
• Human touch: From cutting-edge technology to human-to-human care 
   

#FutureFresenius is clearly paying off

Over the past two years, we have driven structural productivity and improved returns, creating a simpler, more focused, and stronger healthcare company – delivering clear shareholder value! Key milestones include deconsolidating Fresenius Medical Care, concluding several important strategic portfolio measures, and exiting Vamed.

In 2025, we enter the next phase in our transformation “Rejuvenate”: building on our financial successes with a focus on organic growth and capital allocation. Structural productivity remains a priority, with Fresenius Kabi setting the benchmark for achieving sustainable savings and now Fresenius Helios launching a dedicated performance program. We are raising our margin ambitions at Fresenius Kabi, reducing debt, advancing our product pipeline with new launches and improving patient care along our dedicated platforms. 
 

Overview of #FutureFresenius transformation: 

• RESET: First we simplified our group structure, optimized our financial management system, and created change momentum across the organization.
• REVITALIZE: We then geared up for continuous portfolio optimization and the pursuit of growth verticals. 
• REJUVENATE: We are now driving platform-driven growth through product launches and add-ons, and creating value from investments.
• REIMAGINE: Our further enhanced capabilities will allow us to actively shape the future of healthcare!